The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Key factors guiding CAR-T vs bispecific selection in FL: clinical and patient considerations
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses treatment selection between CAR T-cell therapy and bispecific antibodies for follicular lymphoma (FL), emphasizing the lack of randomized data favoring either approach. Dr Alderuccio highlights prior bendamustine exposure as a key consideration due to its potential impact on CAR-T efficacy, with patient preferences helping to guide treatment decisions. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In follicular lymphoma, bispecifics and CAR-T have shown significant activity. There is no randomized data that tells us which treatment is better than the other. There is retrospective data showing a better progression-free survival of CAR-T compared to bispecifics, but without an overall survival benefit. I think the main factor to consider is if the patient received bendamustine previously. CAR-T studies have shown a lower efficacy in patients that receive bendamustine within 12 months of CAR-T...
In follicular lymphoma, bispecifics and CAR-T have shown significant activity. There is no randomized data that tells us which treatment is better than the other. There is retrospective data showing a better progression-free survival of CAR-T compared to bispecifics, but without an overall survival benefit. I think the main factor to consider is if the patient received bendamustine previously. CAR-T studies have shown a lower efficacy in patients that receive bendamustine within 12 months of CAR-T. So those are patients that are selected with bispecifics, but otherwise it’s a discussion with the patient depending on the support, if they prefer a single-time therapy or a continuous or a fixed-duration therapy that can be used to make that decision.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
